PT1524975E - Sistema aperfeicoado de administracao transdermica para a administracao de rotigotina - Google Patents

Sistema aperfeicoado de administracao transdermica para a administracao de rotigotina

Info

Publication number
PT1524975E
PT1524975E PT03766331T PT03766331T PT1524975E PT 1524975 E PT1524975 E PT 1524975E PT 03766331 T PT03766331 T PT 03766331T PT 03766331 T PT03766331 T PT 03766331T PT 1524975 E PT1524975 E PT 1524975E
Authority
PT
Portugal
Prior art keywords
rotigotine
matrix
administration
tds
microreservoirs
Prior art date
Application number
PT03766331T
Other languages
English (en)
Inventor
Hannay Mike
Schacht Dietrich Wilhelm
Hans-Michael Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of PT1524975E publication Critical patent/PT1524975E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT03766331T 2002-07-30 2003-07-28 Sistema aperfeicoado de administracao transdermica para a administracao de rotigotina PT1524975E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system for the administration of rotigotine

Publications (1)

Publication Number Publication Date
PT1524975E true PT1524975E (pt) 2006-07-31

Family

ID=30011090

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03766331T PT1524975E (pt) 2002-07-30 2003-07-28 Sistema aperfeicoado de administracao transdermica para a administracao de rotigotina

Country Status (19)

Country Link
EP (2) EP1386605A1 (pt)
JP (2) JP4837916B2 (pt)
KR (1) KR101016838B1 (pt)
CN (2) CN1671375A (pt)
AT (1) ATE322263T1 (pt)
AU (1) AU2003258539B2 (pt)
BR (1) BR0313091A (pt)
CA (1) CA2491366A1 (pt)
DE (1) DE60304477T2 (pt)
DK (1) DK1524975T3 (pt)
ES (1) ES2256780T3 (pt)
IL (1) IL165918A0 (pt)
MX (1) MXPA05000350A (pt)
NO (1) NO333297B1 (pt)
PL (1) PL217079B1 (pt)
PT (1) PT1524975E (pt)
SI (1) SI1524975T1 (pt)
WO (1) WO2004012730A1 (pt)
ZA (1) ZA200500252B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP2008514376A (ja) * 2004-09-29 2008-05-08 シュウォーツ ファーマ インコーポレイテッド パーキンソン病のための経皮治療システム
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
JP2012504609A (ja) * 2008-10-06 2012-02-23 マイラン・テクノロジーズ，インコーポレイテッド アモルファスロチゴチン経皮システム
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
HRP20181173T1 (hr) 2009-12-22 2018-09-21 Ucb Biopharma Sprl Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
CN103476404B (zh) 2011-03-24 2017-09-29 帝国制药美国公司 包含活性剂层和活性剂转化层的透皮组合物
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
CA2878376C (en) * 2012-07-05 2018-08-07 Sk Chemicals Co., Ltd. Transdermally absorbable preparation containing rotigotine
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014198423A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
JP6895755B2 (ja) * 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
JP6573913B2 (ja) * 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
EP4238580A3 (en) * 2014-05-20 2023-10-25 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
CN104382850B (zh) * 2014-10-17 2017-12-22 烟台大学 一种罗替戈汀微乳及微乳凝胶
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
PL3854388T3 (pl) 2020-01-24 2024-02-26 Luye Pharma Switzerland Ag Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
ATE246919T1 (de) * 2001-05-08 2003-08-15 Sanol Arznei Schwarz Gmbh Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system

Also Published As

Publication number Publication date
EP1524975B9 (en) 2012-02-22
BR0313091A (pt) 2005-06-21
DE60304477T2 (de) 2006-12-14
EP1386605A1 (en) 2004-02-04
IL165918A0 (en) 2006-01-15
AU2003258539A1 (en) 2004-02-23
SI1524975T1 (sl) 2006-06-30
CN101953819A (zh) 2011-01-26
CA2491366A1 (en) 2004-02-12
JP4837916B2 (ja) 2011-12-14
KR20050056942A (ko) 2005-06-16
ATE322263T1 (de) 2006-04-15
AU2003258539B2 (en) 2008-08-21
WO2004012730A1 (en) 2004-02-12
NO20050472L (no) 2005-01-27
ZA200500252B (en) 2006-01-25
EP1524975B1 (en) 2006-04-05
EP1524975A1 (en) 2005-04-27
PL374814A1 (en) 2005-10-31
DE60304477D1 (de) 2006-05-18
KR101016838B1 (ko) 2011-02-22
CN1671375A (zh) 2005-09-21
ES2256780T3 (es) 2006-07-16
PL217079B1 (pl) 2014-06-30
MXPA05000350A (es) 2005-03-31
JP2011219485A (ja) 2011-11-04
DK1524975T3 (da) 2006-07-31
JP5564469B2 (ja) 2014-07-30
NO333297B1 (no) 2013-04-29
JP2005535687A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
BR0313091A (pt) Sistema de liberação transdérmica aperfeiçoado para a administração de rotigotina
DE60309329D1 (de) Verbessertes transdermales abgabesystem
DK1418894T3 (da) Transdermalt terapeutisk system med fentanyl
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
MY109926A (en) Transdermal therapeutic system comprising galanthamine as active component
DE60314298D1 (de) Therapeutisches pflaster mit capsaicin-haltiger polysiloxan-matrix
MY105347A (en) Transdermal therapeutic system comprising as active component buprenorphine
AR093940A1 (es) Sistema de liberacion transdermica, metodo de preparacion
AR050621A1 (es) Sistema terapeutico transdermal con una capa adherente procedimiento para el siliconado de una capa de respaldo y empleo de la capa de respaldo
WO2001068060A3 (de) Stabilisierte übersättigte transdermale therapeutische matrixsysteme
ATE396714T1 (de) Transdermales therapeutisches system mit verbessertem langzeittragekomfort
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
ATE190481T1 (de) Transdermales pflaster aus schaumschichtstoff
CA2387143A1 (en) Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
MX2009008993A (es) Dispositivo para la administracion percutanea de bisoprolol.
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
DK0379933T3 (da) Superficielt behandlingssystem med indhold af et antineoplastisk aktivstof, især 5-fluoruracil
PT1011674E (pt) Sistema terapeutico transdermico com a substancia activa escopolamina base
PT92650A (pt) Processo para a preparacao de um sistema terapeutico transdermico contendo norpseudoefedrina como ingrediente activo
TW200719902A (en) Solid transdermal therapeutic system with uv absorber
DE20221159U1 (de) Transdermales therapeutisches System mit Fentanyl bzw. verwandten Substanzen